New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
New Alzheimer’s Drug Slows Cognitive Decline in Clinical Trial
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
The Biogen-developed treatment, called lecanemab, appears to have a more clear-cut effect on slowing the disease than the company’s previous Alzheimer’s drug, Aduhelm.
Researchers say they hope to launch a clinical trial to test bumetanide, a diuretic approved in 2002, but how it might improve neural functioning is unclear.
The US Food and Drug Administration has called for a federal investigation of its own regulatory review process after widespread criticism of its decision on Aduhelm.
After six months, patients with fast-progressing amyotrophic lateral sclerosis who had received the experimental treatment had less loss of function than those who received a placebo.
A look at some of the circulating molecules that may indicate various Alzheimer’s pathologies and serve as the bases of noninvasive tests for the disease.
Researchers hope circulating biomarkers will enable earlier detection and better monitoring of the neurodegenerative disorder—and perhaps help usher in new treatments.